Video

Inside Cardiology: Bempedoic Acid

Practical Cardiology's Chief Advisory Board member Dr. Guy Mintz and a principal investigator from the CLEAR program discuss bempedoic acid and how they envision it fitting into treatment algorithms going forward.

In this episode of Inside Cardiology, Practical Cardiology's Chief Advisory Board member Guy Mintz, MD, has a lengthy discussion with Steve Nissen, MD, of the Cleveland Clinic, related to bempedoic acid. A novel agent receiving approval in early 2020, bempedoic acid has the potential to help transform treatment algorithms for many lipidologists.

In the interview, Mintz has Nissen, who is also a principal investigator in the pivotal CLEAR program, dive deeper into the mechanism of action of bempedoic acid and where he believes it fits in the next set of guidelines on lipid management. Later in their discussion, Nissen offers insight into the highly-anticipated CLEAR Outcomes trial.

Related Videos
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C | Image Credit: APAC
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Steve Nissen, MD | Credit: Cleveland Clinic
Benjamin Scirica, MD | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.